| pubmed-article:18552145 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18552145 | lifeskim:mentions | umls-concept:C0302592 | lld:lifeskim |
| pubmed-article:18552145 | lifeskim:mentions | umls-concept:C0011923 | lld:lifeskim |
| pubmed-article:18552145 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:18552145 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:18552145 | pubmed:dateCreated | 2008-6-30 | lld:pubmed |
| pubmed-article:18552145 | pubmed:abstractText | Tumor uptake of copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (copper-ATSM), a hypoxia-targeting radiopharmaceutical, assessed by PET has been found to correlate with prognosis in several human cancers. Wide clinical utility of this tracer will require its labeling with a copper radionuclide having a longer half-life than the (60)Cu used in studies to date. The purpose of this work was to obtain the requisite preclinical data for copper-ATSM to file an investigational new drug application, followed by a crossover comparison of PET image quality and tumor uptake with (60)Cu-ATSM and (64)Cu-ATSM in women with cancer of the uterine cervix. | lld:pubmed |
| pubmed-article:18552145 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18552145 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18552145 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18552145 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18552145 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18552145 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18552145 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18552145 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18552145 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18552145 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18552145 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18552145 | pubmed:issn | 0161-5505 | lld:pubmed |
| pubmed-article:18552145 | pubmed:author | pubmed-author:WelchMichael... | lld:pubmed |
| pubmed-article:18552145 | pubmed:author | pubmed-author:DehdashtiFarr... | lld:pubmed |
| pubmed-article:18552145 | pubmed:author | pubmed-author:SiegelBarry... | lld:pubmed |
| pubmed-article:18552145 | pubmed:author | pubmed-author:LewisJason... | lld:pubmed |
| pubmed-article:18552145 | pubmed:author | pubmed-author:GrigsbyPerry... | lld:pubmed |
| pubmed-article:18552145 | pubmed:author | pubmed-author:LaforestRicha... | lld:pubmed |
| pubmed-article:18552145 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18552145 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:18552145 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18552145 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18552145 | pubmed:pagination | 1177-82 | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:meshHeading | pubmed-meshheading:18552145... | lld:pubmed |
| pubmed-article:18552145 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18552145 | pubmed:articleTitle | An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. | lld:pubmed |
| pubmed-article:18552145 | pubmed:affiliation | Division of Radiological Sciences, Mallinckrodt Institute of Radiology, St. Louis, Missouri, USA. lewisj2@mskcc.org | lld:pubmed |
| pubmed-article:18552145 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18552145 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:18552145 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:18552145 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18552145 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18552145 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18552145 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18552145 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18552145 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18552145 | lld:pubmed |
